Guanylyl cyclase c prevents colon cancer metastasis by regulating tumor epithelial cell Matrix metalloproteinase-9

Cancer Research

Volumn 69, Issue 8, 2009, Pages 3529-3536

  Lubbe, Wilhelm J ^a   Zuzga, David S ^a   Zhou, Zengyi ^b   Fu, Weili ^b   Pelta Heller, Joshua ^a   Muschel, Ruth J ^b   Waldman, Scott A ^a   Pitari, Giovanni M ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CYCLIC GMP; ENTEROTOXIN; GELATINASE B; GUANYLATE CYCLASE; GUANYLATE CYCLASE C; HORMONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER PREVENTION; CELL COMPARTMENTALIZATION; CELL CULTURE; CELL ORGANELLE; CELLULAR DISTRIBUTION; COLON CANCER; CONTROLLED STUDY; CYTOSKELETON; DISEASE COURSE; ENZYME ACTIVITY; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; INTESTINE TUMOR; LOCOMOTION; MALE; METASTASIS; MOUSE; NONHUMAN; PERITONEUM; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN TARGETING;

CACO-2 CELLS; CELL LINE, TUMOR; CELL MOVEMENT; COLONIC NEOPLASMS; CYCLIC GMP; EPITHELIAL CELLS; GUANYLATE CYCLASE; HUMANS; MATRIX METALLOPROTEINASE 9; NEOPLASM METASTASIS; PERITONEAL NEOPLASMS; RECEPTORS, PEPTIDE; SIGNAL TRANSDUCTION;

EID: 65949108601     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0067     Document Type: Article

References (47)

1. American Cancer Society. Cancer facts&figures 2008. Atlanta: American Cancer Society, 2008.
2. Sobrero A, Kerr D, Glimehus B. et al. Mew directions in the treatment of colorectal cancer: a look to the future. Eur J. Cancer 2000; 36: 559-66. (Pubitemid 30156840)
3. Meyerhardt JA, Mayer KJ. Systemic therapy for colorectal cancer. N Engl J. Med 2005; 352: 476-87.
4. Jemal A, Tiwari RC, Murray T. et al. Cancer statistics, 2004. CA Cancer J. Clin. 2004; 54: 8-29.
5. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 2003; 3: 453-8. (Pubitemid 37328849)
6. Coussens LM, Fingleton R, Matrisian LM. Matrix met al.loproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-92. (Pubitemid 34270240)
7. Fridman R, Toth M, Chvyrkova I, Meroueh SO, Mobashery S. Cell surface association of matrix met al.loproteinase-9 (gelatinase B). Cancer Metastasis Rev 2003; 22: 153-66. (Pubitemid 36561055)
8. Curran S, Murray GI. Matrix met al.loproteinases in tumour invasion and metastasis, J. Pathol 1999; 189: 300-8.
9. Legrand C, Gilles C, Zahm JM. et al. Airway epithelial cell migration dynamics. MMP-9 role in cell-extracellular matrix remodeling, J. Cell Biol. 1999; 146: 517-29.
10. Sanceau J, Truchet S, Rauvois B. Matrix met al.loproteinase-9 silencing by RNA interference triggers the migratory-adhesive switch in Ewing's sarcoma cells. J. Biol. Chem 2003; 278: 36537-46. (Pubitemid 37139984)
11. Weaver AM. Invadopodia: specialized cell structures for cancer invasion. Clin. Exp Metastasis 2006; 23: 97-105. (Pubitemid 44440169)
12. Zuzga D, Gibbons AV, Li P. et al. Overexpression of matrix met al.loproteinase 9 in tumor epithelial cells correlates with colorectal cancer metastasis. Clin. Transl Sci 2008; 1: 136-41.
13. Eubbe WJ, Zhou ZY, Fu W. et al. Tumor epithelial cell matrix met al.loproteinase-9 is a target for antimetastatic therapy in colorectal cancer. Clin. Cancer Res 2006; 12: 1876-82.
14. Baker EA, Leaper DJ. Profiles of matrix met al.loproteinases and their tissue inhibitors in intraperitoneal drainage fluid: relationship to wound healing. Wound Repair Regen 2003; 11: 268-74. (Pubitemid 36897523)
15. Okada S, Kita H, George TJ, Gleich GJ, Leiferman KM. Migration of eosinophils through basement membrane components in vitro: role of matrix met al.loproteinase-9. Am J. Respir Cell Mol. Biol. 1997; 17: 519-28. (Pubitemid 127500985)
16. St-Pierre Y, Van Themsehe C, Esteve PO. Emerging features in the regulation of MMP-9 gene expression for the development of novel molecular targets and therapeutic strategies. Curr Drug Targets Inflamm Allergy 2003; 2: 206-15.
17. Zhang Q, Furukawa K, Chen HH. et al. Metastatic potential of mouse Lewis lung cancer cells is regulated via ganglioside GM1 by modulating the matrix met al.loprotease-9 localization in lipid rafts, J. Biol. Chem 2006; 281: 18145-55. (Pubitemid 44035614)
18. Akool el S, Kleinert H, Hamada FM. et al. Nitric oxide increases the decay of matrix met al.loproteinase 9 mRNA by inhibiting the expression of mRNA-stabilizing factor HuR. Mol. Cell Biol. 2003; 23: 4901-16. (Pubitemid 36793336)
19. Gurjar MV, Sharma RV, Bhalla RC. eKOS gene transfer inhibits smooth muscle cell migration and MMP-2 and MMP-9 activity. Arterioscler Thromb Vasc Biol. 1999; 19: 2871-7. (Pubitemid 30029812)
20. Lucas KA, Pitari GM, Kazerounian S. et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 2000; 2: 75-414.
21. Schulz S, Green CK, Yuen PS, Garbers DL. Guanylyl cyclase is a heat-stable enterotoxin receptor. Cell 1990; 63: 941-8. (Pubitemid 120034935)
22. Giannella RA. Escherichia coli heat-stable enterotoxins, guanylins, and their receptors: what are they and what do they do? J. Lab Clin. Med 1995; 125: 173-81.
23. Almenoff JS, Williams SI, Scheving LA, Judd AK, Schoolnik GK. Ligand-based histochemical localization and capture of cells expressing heat-stable enterotoxin receptors. Mol. Microbiol 1993; 8: 865-73. (Pubitemid 23171468)
24. Carrithers SL, Parkinson SJ, Goldstein S. et al. Escherichia coli heat-stable toxin receptors in human colonic tumors. Gastroenterology 1994; 107: 1653-61. (Pubitemid 124006525)
25. Carrithers SL, Barber MT, Biswas S. et al. Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proc. Natl. Acad. Sci. V S A 1996; 93: 14827-32. (Pubitemid 26419054)
26. Schulz S, Hyslop T, Haaf J. et al. A validated quantitative assay to detect occult mierometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin. Cancer Res 2006; 12: 4545-52. (Pubitemid 44297803)
27. Pitari GM, Li P, Lin JE. et al. The paracrine hormone hypothesis of colorectal cancer. Clin. Pharmacol Ther. 2007; 82: 441-7. (Pubitemid 47414353)
28. Pitari GM, Di Guglielmo MD, Park J, Schulz S, Waldman SA. Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells. Proc. Natl. Acad. Sci. U S A 2001; 98: 7846-51. (Pubitemid 32642649)
29. Olson MW, Gervasi DC, Mobashery S, Fridman R. Kinetic analysis of the binding of human matrix met al.loproteinase-2 and -9 to tissue inhibitor of met al.loproteinase (TIMP) -l and TIMP-2. J. Biol. Chem 1997; 272: 29975-83. (Pubitemid 27508102)
30. Collins HM, Morris TM, Watson SA. Spectrum of matrix met al.loproteinase expression in primary and metastatic colon cancer: relationship to the tissue inhibitors of met al.loproteinases and membrane type- 1-matrix met al.loproteinase. Br J. Cancer 2001; 84: 1664-70. (Pubitemid 32612499)
31. Al-Mehdi AB, Tozawa K, Fisher AB. et al. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med 2000; 6: 100-2. (Pubitemid 30048535)
32. Li P, Lin JE, Chervoneva I. et al. Homeostatic regulation of the crypt-to-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine. Am J. Pathol 2007; 171: 1847-58.
33. Li P, Schulz S, Bombonati A. et al. Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology 2007; 133: 599-607. (Pubitemid 47187356)
34. Pitari GM, Zingman LV, Hodgson DM. et. al.Bacterial enterotoxins are associated with resistance to colon cancer. Proc. Natl. Acad. Sci. U S A 2003; 100: 2695-9. (Pubitemid 36297561)
35. Carrithers SL, Parkinson SJ, Goldstein SD. et al. Escherichia coli heat-stable enterotoxin receptors. A novel marker for colorectal tumors. Dis Colon Rectum 1996; 39: 171-81. (Pubitemid 26050896)
36. Clark ES, Whigham AS, Yarbrough WG, Weaver AM. Cortactin is an essential regulator of matrix met al.loproteinase secretion and extracellular matrix degradation in invadopodia Cancer Res 2007; 67: 4227-35. (Pubitemid 46815069)
37. Koyama Y, Naruo H, Yoshitomi Y. et al. Matrix met al.loproteinase-9 associated with heparan sulphate chains of GPI-anchored cell surface proteoglycans mediates motility of murine colon adenocarcinoma cells, J. Biochem 2008; 143: 581-92.
38. Bergers G, Brekken R, McMahon G. et al. Matrix met al.loproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000; 2: 737-44.
39. Deryugina EI, Quigley JP. Matrix met al.loproteinases and tumor metastasis. Cancer Metastasis Rev 2006; 25: 9-34. (Pubitemid 43723979)
40. Overall CM, Kleifeld O. Tumour microenvironment. Opinion: validating matrix met al.loproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 2006; 6: 227-39.
41. Martin MD, Matrisian LM. The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev 2007; 26: 717-24. (Pubitemid 350115119)
42. 6 integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix met al.loproteinase-9. Int J. Cancer 2001; 92: 641-50. (Pubitemid 32385704)
43. 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity, Int J. Cancer 2000; 87: 336-42. (Pubitemid 30451643)
44. 6 integrin induces gelatinase B secretion in colon cancer cells. Int J. Cancer 1999; 81: 90-7. (Pubitemid 29124202)
45. Williams TM, Medina F, Badano I. et al. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix met al.loproteinase (MMP-2/9) secretion. J. Biol. Chem 2004; 279: 51630-46.
46. Notterman DA, Alon U, Sierk AJ, Levine AJ. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res 2001; 61: 3124-30. (Pubitemid 32691964)
47. Rirkenkamp-Demtroder K, Lotte Christensen L, Harder Olesen S. et al. Gene expression in colorectal cancer. Cancer Res 2002; 62: 4352-63.